BNCT clinical trials

Phase II clinical trials

The start dates are shown below for two phase II trials using a 10B compound formulation developed by Stella Pharma and an accelerator-based BNCT system created by Sumitomo Heavy Industries.

Phase II trial for recurrent malignant glioma December 2015
Phase II trial for head and neck cancer June 2016
Boron formulation by Stella Pharma Boron Formulation by Stella Pharma
Accelerator-based BNCT system by Sumitomo Heavy Industries Accelerator-based BNCT system by Sumitomo Heavy Industries

World’s first BNCT trials

  • Recurrent malignant glioma Phase II clinical trial started in December 2015
  • Head and neck cancer Phase II clinical trial started in June 2016

Drug approval process

  • Phase I clinical trials
    Studies of
    irradiation dosage safety
  • Phase II clinical trials
    Studies of
    irradiation dosage effectiveness
  • Application for approval